Revolutions Medical begins mass manufacturing process for safety syringe

Revolutions Medical Corporation ("RevMed" or the "Company") (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it has initiated the mass manufacturing process for the RevVac safety syringe, which is already FDA approved. By hitting its primary milestone, RevMed satisfies its previously announced commitment to begin production in Q4 '09. It also stays on pace to meet its Q2 '10 sales launch goal and $14.8 million 2010 revenue projection.

"After years in developing what we believe is the world's best safety syringe, we are extremely pleased to announce that the plan is now reality -- we have launched the mass manufacturing process for the RevVac safety syringe," stated Revolutions Medical CTO Richard Theriault. "This constitutes the next step toward full scale high volume production and commercialization. With this first phase we will 1) provide market-ready samples and 2) complete the steps necessary to ensure ultimate delivery of a high quality, high volume manufacturing solution. We have been working closely with the team at Goddard Technologies (www.goddardtech.com) -- the group responsible for the recent crucial product refinements -- towards this, our primary pre-sales milestone. We remain precisely on pace with our stated goals, and we can now demonstrate tangible progress toward bringing the much-anticipated RevVac to market in Q2 '10."

Andrew Goddard, President of Goddard Technologies, stated, "We are pleased to be working with Revolutions Medical on the first phase of the RevVac Safety Syringe mass manufacturing process. The RevVac design is unique and elegant as an easy to use, single-handed vacuum safety syringe. That we could contribute to a product of such high caliber is a source of great pride for Goddard Technologies."